1. Home
  2. HAPN vs ZYME Comparison

HAPN vs ZYME Comparison

Compare HAPN & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Happen Inc. Common Stock

HAPN

Happen Inc. Common Stock

N/A

Current Price

$15.80

Market Cap

1.7B

Sector

Finance

ML Signal

N/A

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

N/A

Current Price

$29.96

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HAPN
ZYME
Founded
2006
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
2.0B
IPO Year
2008
2022

Fundamental Metrics

Financial Performance
Metric
HAPN
ZYME
Price
$15.80
$29.96
Analyst Decision
Buy
Strong Buy
Analyst Count
8
14
Target Price
$23.88
★ $42.43
AVG Volume (30 Days)
★ 2.5M
1.2M
Earning Date
10-28-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 157.78
33.33
EPS
★ 1.44
1.08
Revenue
★ $314,702,000.00
$105,965,000.00
Revenue This Year
N/A
$195.79
Revenue Next Year
$21.71
$14.68
P/E Ratio
★ $10.94
$29.51
Revenue Growth
N/A
★ 38.87
52 Week Low
$13.73
$18.20
52 Week High
$21.25
$31.97

Technical Indicators

Market Signals
Indicator
HAPN
ZYME
Relative Strength Index (RSI) 53.65 57.38
Support Level $13.82 $22.23
Resistance Level $21.25 $31.34
Average True Range (ATR) 0.67 1.34
MACD 0.16 0.19
Stochastic Oscillator 67.04 58.42

Price Performance

Historical Comparison
HAPN
ZYME

About HAPN Happen Inc. Common Stock

Happen Inc is a U.S. digital marketplace bank focused on the Motivated Middle - high FICO, high-income borrowers actively managing their financial lives. The bank's success is fueled by evolved credit underwriting, a proprietary technology platform, and a marketplace bank model that generates compelling revenue through loan sales, net interest income, and fee-based services.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: